The U.S. Department of Veterans Affairs (VA) recognizes viral
hepatitis as a highly prevalent chronic disease among Veterans in VA
care. VA continues to be proactive in addressing viral hepatitis, and is
actively taking part in the implementation of the Action Plan for the Prevention, Care and Treatment of Viral Hepatitis, which is led by the U.S. Department of Health and Human Services (HHS).
Chronic viral hepatitis is a major public health problem in the
United States because of the millions of persons who are chronically
infected and because of the potential for untreated viral hepatitis to
progress to cirrhosis, liver cancer, and other life-threatening
conditions.Hepatitis C virus (HCV) and hepatitis B virus (HBV) are the major causes of chronic viral hepatitis in the U.S.
GlaxoSmithKline (NYSE:GSK) now wants approval to use its low platelet drug Promacta to treat hepatitis C patients.
GSK has filed regulatory applications in Europe and the United States to add the new indication to the drug. The drug eltrombopag, which is marketed under the brand name Promacta in the United States and Revolade globally, is approved in 88 countries to treat immune thrombocytopenia, a condition in which a patient has low blood counts because the platelets are destroyed by his own immune system. The condition puts patients at the risk of bleeding. Promacta was codiscovered by GSK predecessor SmithKline Beecham and partner Ligand Pharmaceuticals.
A needle exchange program that aims to reduce new cases of HIV, AIDS and hepatitis C has reached 90 drug users in Syracuse.
Since January, AIDS Community Resources, a nonprofit group that
provides HIV/AIDS prevention and support services, said it has
distributed syringes to 90 people each week from a van that visits areas
of the city where drug abusers are known to congregate.
Jerusalem and Rehovot, Israel; Seoul, South Korea, May 29, 2012 —
The discovery of a mummified Korean child with relatively preserved
organs enabled an Israeli-South Korean scientific team to conduct a
genetic analysis on a liver biopsy which revealed a unique hepatitis B
virus (HBV) genotype C2 sequence common in Southeast Asia.
Additional analysis of the ancient HBV genomes may be used as a
model to study the evolution of chronic hepatitis B and help understand
the spread of the virus, possibly from Africa to East-Asia. It also may
shed further light on the migratory pathway of hepatitis B in the Far
East from China and Japan to Korea as well as to other regions in Asia
and Australia where it is a major cause of cirrhosis and liver cancer.
Scientists at the Genome Institute of Singapore (GIS) have
unraveled the mechanism that causes liver cancer (hepatocellular
carcinoma, HCC), one of the most common solid tumors worldwide. This
genome-wide research was done in collaboration with colleagues from the
National University of Singapore (NUS), University of Hong Kong, Eli
Lilly & Co. USA, Merck Research Laboratories USA, Pfizer Oncology
USA and Beijing Genomics Institute China.
The discovery was published in the prestigious scientific journal, Nature Genetics,
on 27 May 2012. The GIS is a research institute under the umbrella of
the Agency for Science, Technology and Research (A*STAR).
One major cause of liver cancer,
or HCC, is high exposure to the hepatitis B virus (HBV), resulting in
the integration of HBV into the victim’s genes. Individuals who carry
the HBV have a greater than 100-fold increased relative risk of
developing HCC, considered to be a serious global health problem by the
World Health Organization (WHO).
Introducing the guidelines: John Ward, MD – Division Director, CDC Division of Viral Hepatitis (DVH)
Supportive Research: Bryce Smith, Ph.D. – Team Lead, Prevention Research and Evaluation Team, CDC DVH
Community Call to Action: Ryan Clary – Director of Public Policy, Project Inform & NVHR Executive Committee Secretary
** The document is located at: www.regulations.gov. Search for Docket ID: CDC_2012_0005.
This page will provide you with the opportunity to view the Federal
Register Notice of the posting of this draft, as well as the actual
recommendations. Comments on the recommendations
can be submitted through a link on the page for the notice
Thanks to Caring Ambassadors for making this webinar possible.
COLUMBUS, Ga. –John Bloszies has been a Veterinarian for thirty years. That’s
how long he had hepatitis C before he found out. He had entered a new
age bracket, causing his insurance premiums to go up. He found another
plan, but needed a physical. That’s when they found it.
“And he called me and I was incredulous, I said are you kidding,” says Bloszies.